![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Alzheimer’s Drug Put on Fast Track
Alzheimer’s Drug Put on Fast Track
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
October 27, 2017
The FDA conferred fast-track status on an Alzheimer’s disease drug from Alzheon.
The drug, ALZ-801, is an optimized prodrug of tramiprosate that has shown promise in clinical trials, the company said.
The forthcoming Phase 3 program for ALZ-801 will focus initially on a genetically-defined group of high-risk patients who are homozygous for the ε4 allele of apolipoprotein E (APOE4/4 homozygotes) in the mild stage of the disease. The target population could be expanded in further investigations of the treatment.
Upcoming Events
-
21Oct